PTHN Patheon N.V.

Patheon Named Supply Chain Resiliency Partner of the Year

Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that the company was selected as the winner of the “Supply Chain Resiliency Partner of the Year” award by the Global Supply Chain Resiliency Council. The award was presented at RESILIENCE 2017, the Annual Global Supply Chain Resiliency Council Conference and Awards Gala on Wednesday, March 1, 2017, in Silicon Valley, CA.

The awards program is designed to recognize organizations and individuals that serve as role models and leaders in driving supply chain resiliency strategy success within their company, supply chain network, and across industries. The awards committee considered nominations from across the industry, including its general membership of over 1000 members worldwide comprised of OEMs/brand owners, suppliers, and experts from the Council’s technical advisor, Resilinc.

Selection of the Partner of the Year winner was based on a number of criteria and input related to customer collaboration practices and culture, technology adoption, and overall maturity-level of processes and best practices, as well as the organization’s commitment to institutionalize best practices and demonstrate innovation and continuous improvement over time.

“Patheon is honored to be recognized for excelling in customer collaboration and innovation. The company is committed to developing solutions to supply chain challenges to help us deliver on the promise of a fully integrated supply chain for our customers,” said Rebecca Holland New, executive vice president, enterprise operations, Patheon.

Bill Hurles, Executive Director Global Supply Chain Resiliency Council said, “Patheon has taken the key steps to transform a complex and fragmented supply chain problem by implementing ways to reduce risk, not only for themselves, but for the customers who count on their services.”

About The Global Supply Chain Resiliency Council

The Global Supply Chain Resiliency Council was formed to bring together supply chain risk management and resiliency practitioners with luminaries and thought leaders to advance the professional discipline through opportunities to collaborate, share best practices, and be recognized for innovation and leadership. The awards program is designed to recognize organizations and individuals that serve as role models and leaders in driving supply chain resiliency strategy success within their company, supply chain community, and across industries.

About Patheon

Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help clients of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. A Healthier World. Delivered. www.patheon.com

EN
02/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Patheon N.V.

 PRESS RELEASE

Patheon Announces Intent to Voluntarily Delist from the NYSE Subject t...

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (NYSE: PTHN) (“Patheon”), today announced that it has submitted written notice to the New York Stock Exchange (the “NYSE”) of its intention to voluntarily delist its ordinary shares, par value €0.01 per share (the “Shares”), from the NYSE. The voluntary delisting is subject to and conditioned upon (1) the initial expiration of the tender offer at 5:00 p.m., New York City time, on August 2...

 PRESS RELEASE

Patheon to Invest $45 Million, Expanding Capabilities to Support Conti...

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, today announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. “As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even more advanced technologies and customized solutions to meet their ...

 PRESS RELEASE

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Patheon N.V. (NYSE:PTHN) stock prior to May 15, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Patheon to Thermo Fisher Scientific Inc. (NYSE:TMO) for $35 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/PTHN-Info-Request-Form-ma-5885 or contact J...

 PRESS RELEASE

Patheon Reports Fiscal 2017 Second Quarter

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017. Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $941 million, compared to $875 million in the comparable fisc...

 PRESS RELEASE

Patheon Completes Sterile Expansion Project at Greenville, NC Manufact...

DURHAM, N.C.--(BUSINESS WIRE)-- Patheon N.V (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suite which are compliant with regulatory authorities. The PDS Sui...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch